Tewari, K. S., Vergote, I., Oaknin, A., Alvarez, E., Gaillard, S., Lheureux, S., … Monk, B. J. (2018). GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29, ix86. https://doi.org/10.1093/annonc/mdy436.027

Tewari, K. S., I. Vergote, A. Oaknin, E. Alvarez, S. Gaillard, S. Lheureux, D. Rischin, et al. “GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (November 1, 2018): ix86. https://doi.org/10.1093/annonc/mdy436.027.

Tewari KS, Vergote I, Oaknin A, Alvarez E, Gaillard S, Lheureux S, et al. GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Nov 1;29:ix86.

Tewari, K. S., et al. “GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, Nov. 2018, p. ix86. Scopus, doi:10.1093/annonc/mdy436.027.

Tewari KS, Vergote I, Oaknin A, Alvarez E, Gaillard S, Lheureux S, Rischin D, Santin AD, Feng M, Mathias M, Fury M, Lowy I, Monk BJ. GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Nov 1;29:ix86.